XTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

XTX Topco Ltd acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 90,191 shares of the company’s stock, valued at approximately $565,000. XTX Topco Ltd owned about 0.13% of Phathom Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PHAT. GAMMA Investing LLC lifted its position in Phathom Pharmaceuticals by 797.2% in the first quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock valued at $29,000 after acquiring an additional 4,050 shares during the last quarter. CWM LLC lifted its position in Phathom Pharmaceuticals by 20,997.1% in the first quarter. CWM LLC now owns 7,384 shares of the company’s stock valued at $46,000 after acquiring an additional 7,349 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Phathom Pharmaceuticals in the fourth quarter valued at $74,000. Rafferty Asset Management LLC purchased a new stake in Phathom Pharmaceuticals in the fourth quarter valued at $90,000. Finally, ProShare Advisors LLC lifted its position in Phathom Pharmaceuticals by 36.3% in the fourth quarter. ProShare Advisors LLC now owns 14,289 shares of the company’s stock valued at $116,000 after acquiring an additional 3,804 shares during the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Stock Up 3.6%

Shares of Phathom Pharmaceuticals stock opened at $8.68 on Thursday. Phathom Pharmaceuticals, Inc. has a 52-week low of $2.21 and a 52-week high of $19.71. The company’s 50-day simple moving average is $8.60 and its 200-day simple moving average is $6.24. The firm has a market cap of $605.95 million, a price-to-earnings ratio of -1.66 and a beta of 0.45.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Phathom Pharmaceuticals in a research report on Monday, June 9th. The Goldman Sachs Group dropped their price objective on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. Guggenheim dropped their price objective on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, Craig Hallum lifted their price objective on shares of Phathom Pharmaceuticals from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, June 9th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $17.50.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.